Re: Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

No AccessJournal of UrologyUrological Survey1 Jan 2020Re: Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer Samir S. TanejaMD Samir S. TanejaSamir S. Taneja More articles by this author View All Author Informationhttps://doi.org/10.1097/01.JU.0000611504.41578.eeAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail "Re: Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer." The Journal of Urology, 203(1), pp. 32–33 Suggested Reading : Androgen receptor targeted treatments of prostate cancer: 35 years of progress with antiandrogens. J Urol 2018; 200: 956. Link, Google Scholar : Long-term antitumor activity and safety of enzalutamide monotherapy in hormone naïve prostate cancer: 3-year open label followup results. J Urol 2018; 199: 459. Link, Google Scholar © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue 1January 2020Page: 32-33 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Samir S. Taneja More articles by this author Expand All Advertisement PDF downloadLoading ...